Gynecol Oncol 2020 Jan 20
Low-grade serous ovarian cancer: State of the science.
Abstract
In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.
Related Questions
What is your preferred adjuvant regimen for an optimally cytoreduced, stage III low grade serous ovarian carcinoma?
My decision for adjuvant cytotoxic chemotherapy following initial/primary optimal debulking for advanced Stage III Disease is based upon both personal experiences as well as with literature guidance.The initial guiding issues that I use are age and residual disease at completion of therapy. I am ans...
How would you counsel a young patient regarding HRT after BSO for Stage IIIA1 serous borderline tumor?
How would you counsel a young patient regarding HRT after BSO for Stage IIIA1 serous borderline tumor?Path significant for micropapillary features and micro-invasionBOT: borderline ovarian tumorsBOT: serous borderline ovarian tumorLGSOC: low grade serous ovarian cancerHGSOC: high grade serous ovaria...